

Quantitative CT Imaging of the Lung

Saturday, March 10, 2012

Hyatt Regency Huntington Beach

Huntington Beach, California

Program Description

This one-day course, co-sponsored by the Society of Thoracic Radiology and the Quantitative Imaging Biomarkers Alliance, will summarize the current state of knowledge regarding the role of quantitative CT of the lungs in diffuse lung disease.

Learning Objectives

At the completion of the course, the attendee will be able to:

- Describe the technical parameters for performing and quantitatively analyzing CT of the lung parenchyma in diffuse lung diseases;
- Summarize the role of quantitative CT in diffuse lung diseases including asthma, COPD and fibrosing lung diseases;
- Understand the importance of quantitative CT as a biomarker of diffuse lung disease.

Target Audience

Thoracic radiologists, pulmonologists, imaging scientists.

Credit Information

The Society of Thoracic Radiology is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The Society of Thoracic Radiology (STR) designates this live activity for a maximum of **6.25 AMA PRA Category 1 Credits™**. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Course Directors

Jonathan Goldin, MBChB, PhD & David A. Lynch, MB

Course Schedule

8:00 AM	Development of Quantitative CT Lung Protocols <i>John D. Newell, Jr., MD</i>
8:20 AM	What Can We Learn from CT Phantoms? <i>Philip F. Judy, PhD</i>
8:40 AM	Sources of Variation in Quantitative CT of the Lungs <i>Harvey O. Coxson, PhD</i>
9:00 AM	Establishing Normal Reference Values in QCT <i>R. Graham Barr, MD, DrPH</i>
9:20 AM	COPD <i>David A. Lynch, MB</i>
9:40 AM	Group discussion
10:00 AM	BREAK
10:20 AM	Asthma <i>Eric A. Hoffman, PhD</i>
10:40 AM	Fibrosing Interstitial Lung Diseases <i>Brian J. Bartholmai, MD</i>
11:00 AM	Cystic Fibrosis <i>Alan S. Brody, MD</i>
11:20 AM	Clinical Impact of QCT Measurements <i>Donald P. Tashkin, MD</i>

Quantitative CT Imaging of the Lung

Saturday, March 10, 2012

Program Continued

11:40 AM	Panel Discussion <i>Moderators: Hyun J. (Grace) Kim, PhD and David A. Lynch, MB</i>
12:00 PM	LUNCH
1:00 PM	Scientific Presentations <i>Moderators: Matthew S. Brown, PhD and Jonathan Goldin, MBChB, PhD</i>
2:00 PM	Dose Reduction in Quantitative CT <i>Michael F. McNitt-Gray, PhD, DABR</i>
2:20 PM	Quantitative Imaging Biomarkers Alliance <i>Daniel C. Sullivan, MD</i>
2:40 PM	BREAK
3:00 PM	Biomarkers for COPD <i>Stephen Rennard, MD</i>
3:20 PM	FDA Requirements for QCT in Registration Trials <i>Jonathan Goldin, MBChB, PhD</i>
3:40 PM	Discussion, Closing Remarks <i>Jonathan Goldin, MBChB, PhD & David A. Lynch, MB</i>

Faculty

R. Graham Barr, MD, DrPH
Columbia University

Brian J. Bartholmai, MD
Mayo Clinic

Alan S. Brody, MD
Children's Hospital Medical Center

Matthew S. Brown, PhD
UCLA - David Geffen School of Medicine

Harvey O. Coxson, PhD
The University of British Columbia

Jonathan Goldin, MBChB, PhD
UCLA - David Geffen School of Medicine

Eric A. Hoffman, PhD
University of Iowa Hospitals and Clinics

Philip F. Judy, PhD
Brigham and Women's Hospital

Hyun J. (Grace) Kim, PhD
UCLA - David Geffen School of Medicine

David A. Lynch, MB
National Jewish Health

Michael F. McNitt-Gray, PhD, DABR
UCLA - David Geffen School of Medicine

John D. Newell, Jr., MD
University of Iowa

Stephen Rennard, MD
University of Nebraska Medical Center

Daniel C. Sullivan, MD
Duke University

Donald P. Tashkin, MD
UCLA - David Geffen School of Medicine